Personnel at the Integrated Research Facility at Fort Detrick (IRF-Frederick) work in a collaborative manner within and between teams and with external partners and affiliates.
Connie Schmaljohn, Ph.D.
Dr. Connie Schmaljohn was selected and became director of the NIAID IRF-Frederick in November 2019. Prior to that time, she was the senior research scientist for medical defenses against infectious disease threats for the U.S. Army and directed a research program at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).
Dr. Schmaljohn earned a B.S. degree in microbiology from the University of Nebraska and a Ph.D. in virology from Colorado State University, after which she joined USAMRIID as a National Research Council postdoctoral fellow. Her subsequent positions at USAMRIID included principal investigator and chief of molecular virology. Dr. Schmaljohn’s research background is in molecular virology and molecular vaccine development. She has served as president of the International Society of Hantaviruses, chair of the American Society for Microbiology Biodefense Conference, and chair of the International Committee on the Taxonomy of Viruses Bunyaviridae Study Group. She also has served on the Interagency Public Health Emergency Medical Countermeasure Enterprise (PHEMCE) Viral Hemorrhagic Fevers Integrated Product Team (IPT), the Board of Scientific Counselors for the NIAID Vaccine Research Center, and the Scientific Advisory Council for the Coalition of Emergency Preparedness Innovations (CEPI). She was elected to the American Academy of Microbiology (2007) and was selected as fellow of the International Society for Vaccines (2015). She received the Order of Military Merit (2002), the Association of Military Surgeons of the United States Research Award (2002), the University of Nebraska Alumni Achievement Award (2012), and the Presidential Rank Award (2017).
As director, Dr. Schmaljohn provides overall scientific leadership to the research activities of the IRF-Frederick; oversees program operations; recommends, approves, or develops new collaborative research programs to advance medical countermeasures; allocates IRF-Frederick physical and financial resources; and recommends and implements policies for the execution of multi-disciplinary research focusing on the IRF-Frederick’s unique imaging and high containment capabilities. In addition, she serves as an expert consultant and advisor both nationally and internationally on the development of novel vaccine strategies for highly pathogenic viruses.
Ian Crozier, M.D.
Chief Medical Officer and Medical Affairs Scientist (Contractor)
As chief medical officer, Dr. Crozier provides support to bridge the human clinical bedside and animal models of emerging high-threat infectious diseases. He is an infectious diseases clinician-scientist who brings extensive experience with the Ebola virus disease outbreak, including bedside work in Africa as well as ongoing clinical and research efforts in Western Africa and the Democratic Republic of the Congo. Dr. Crozier’s particular interests include the host-filoviral and host-arenaviral determinants of “success” in both acute disease and survivor clinical phenotypes, such as the interaction of viruses with immune-privileged tissues.
Linda M. Coe, R.N., M.S.N.
Associate Director for Management and Operations and Contracting Officer’s Representative (COR)
Ms. Coe has served in her current role at the IRF-Frederick since 2007. Prior to joining the IRF-Frederick, she held positions including Associate Clinical Director and Branch Chief for NIAID’s Division of Clinical Research (DCR) and Clinical Research Nurse and Nurse Manager at the NIH Clinical Center.
Travis K. Warren, Ph.D.
Operations Director (Contractor)
With over 20 years of experience conducting and leading infectious disease research, Dr. Warren’s data from nonclinical studies have contributed to U.S. Food and Drug Administration (FDA) approvals of tecoviromat for treatment of smallpox and remdesivir for treatment of SARS-CoV-2. He specializes in animal rule regulatory model characterizations and therapeutic development for highly infectious viral pathogens. He possesses extensive expertise in managing U.S. government-funded biocontainment assets to advance public-private partnerships with focus toward advanced development of medical countermeasures.
Scientific and Technical Services
Lisa E. Hensley, Ph.D., M.S.P.H.
Associate Director for Science
Dr. Hensley received her training in virology and epidemiology at The Johns Hopkins Bloomberg School of Public Health and the University of North Carolina. She has over 20 years of experience developing animal models and evaluating medical countermeasures for high-consequence pathogens in biocontainment. In addition, Dr. Hensley has extensive experience establishing laboratories to support diagnostic efforts and clinical studies in low-resource settings. She has authored over 200 peer‑reviewed papers and is considered a leading subject matter expert in emerging diseases.
Mike Holbrook, Ph.D.
Principal Scientist and Director of Biocontainment (Contractor)
Dr. Holbrook has been working in biocontainment research for more than 20 years with recognized expertise in biocontainment facilities, resources, and research management. Dr. Holbrook has a broad research portfolio with practical research experience working with arenaviruses, bunyaviruses, filoviruses, flaviviruses, and henipaviruses. His research interests include viral pathogenesis, viral immunology, virus structure, and fundamental aspects of cell biology.
Reed F. Johnson, Ph.D.
Associate Director for High Containment
Dr. Johnson received his Ph.D. from Texas A&M University, followed by a postdoctoral fellowship at the University of Pennsylvania, prior to joining NIH in 2007. With over 20 years of experience, he is an accomplished molecular virologist and has led the IRF-Frederick efforts to incorporate advanced medical imaging technology into animal models of human disease. Dr. Johnson has been an author on over 50 publications.
Jens H. Kuhn, M.D., Ph.D., Ph.D., M.S.
Principal Scientist and Director of Virology (Contractor)
Dr. Kuhn specializes in the molecular biology and pathogenesis of and medical countermeasure development against Risk Group 4 pathogens (in particular, arenaviruses and filoviruses), evolutionary virology and virus taxonomy, and bioweapons defense. Dr. Kuhn has published more than 235 journal articles and 70 book chapters, serves on the editorial boards of 10 journals, and has been a peer reviewer for more than 90 journals.
Marisa St. Claire, D.V.M., M.S., Diplomate ACLAM
Dr. St. Claire oversees the Comparative Medicine Program, including all aspects of animal care and use. She is board-certified by the American College of Laboratory Animal Medicine (ACLAM) and has over 20 years of experience conducting infectious disease research using animal models for NIAID.